
-
Biomea Fusion NASDAQ:BMEA Biomea Fusion, Inc. operates as a biopharmaceutical company. The Company focuseS on the discovery, development, and commercialization of irreversible small molecules to treat patients with genetically defined cancers. Biomea Fusion serves customers in the United States.
Location: | Website: www.biomeafusion.com | Industry: Research and Development in Biotechnology | Sector: Professional, Scientific, and Technical Services
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
23.76M
Cash
58.28M
Avg Qtr Burn
-29.97M
Short % of Float
35.31%
Insider Ownership
14.81%
Institutional Own.
61.28%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BMF-219 (icovamenib) Details Type 2 diabetes | Phase 2b Update | |
Phase 2 Data readout | ||
Phase 2 Initiation | ||
BMF-500 Details Leukemia | Phase 1 Update | |
BMF-219 (icovamenib) Details Acute myeloid leukemia, Acute lymphoblastic leukemia | Failed Discontinued | |
BMF-219 (icovamenib) Details Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma | Failed Discontinued |